Weight and metabolic health
Visceral fat and abdominal adiposity
Visceral fat lies around organs and differs from pinchable subcutaneous fat. Waist change is useful but does not identify the exact tissue compartment.
Potential benefits explored
Reduced abdominal and visceral fat.
Tesamorelin has a defined HIV-associated visceral-fat evidence base. Broader weight-management peptides offer a different route to reducing abdominal size.
Practical interpretation
Use an overall metabolic-health plan and realistic body-composition goals; assess glucose and strength alongside waist.
Meaningful outcomes: Waist and body composition; imaging only where clinically relevant.
Compare the compounds studied for Visceral fat and abdominal adiposity
Members see the full evidence picture for this condition: every compound studied, graded per condition from strong human evidence through to preclinical-only and negative findings, with human and animal results, risks, combination evidence and cited sources — plus how each compound maps to the research materials we list, with live pricing and stock.
Research reference for laboratory materials only. Not medical advice and not a recommendation for human use. Research cut-off: 30 September 2026.